CAR T-cells, which are immune cells reprogrammed to fight cancer, are promising novel cancer therapies to treat certain types of tumors. But, the underlying biological pathways that lead to remission or toxicity are not fully understood. In a study published in...
COVID-19 is an emerging, rapidly evolving siituation.
What people with cancer should know: https://www.cancer.gov/coronavirus
Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers
Get the latest public health information from CDC: https://www.coronavirus.gov
Get the latest research information from NIH: https://www.nih.gov/coronavirus
News and Announcements
All | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010
Displaying 141 - 160 of 256December 4, 2018
The NCI-CPTAC Multi-omics Enabled Sample Mislabeling Correction Challenge sub-challenge 2 closes on December 19 at 07:59:59 UTC. Just two weeks left to submit your compuational algorithms. Remember, if you did not participate in sub-challenge 1, you can still participate in sub-challenge 2.
November 6, 2018
The second data release for the NCI-CPTAC Multi-omics Enabled Sample Mislabeling Correction Challenge has launched! If you did not participate in sub-challenge 1 (submission 1), you can still participate in sub-challenge 2 (submission 2).
November 2, 2018
Several ongoing Phase I clinical trials are assessing the safety and tolerability of ATM (ataxia-telangiectasia mutated) and ATR (ataxia-telangiectasia and Rad3-Related) inhibitors when administered alone or in combination with existing therapies. ATM and ATR are attractive therapeutic targets in...
October 23, 2018
The security of precisionFDA users’ personal information and data is of critical importance. To strengthen the safeguards already in place, precisionFDA will be introducing several changes to achieve compliance with the FedRAMP and FISMA Moderate security standards. These changes will take effect...
October 16, 2018
The Clinical Proteomic Tumor Analysis Consortium (CPTAC) is releasing the latest proteomic discovery datasets for Uterine Corpus Endometrial Carcinoma (UCEC) and Clear Cell Renal Cell Carcinoma (ccRCC). CPTAC has previously demonstrated how proteogenomics reveals new insights into cancer biology....
October 9, 2018
Fanconi anemia (FA) is a rare inherited disorder characterized by progressive bone marrow failure and an increased risk of developing certain types of cancer. The FA pathway consists of a network of 21...
October 1, 2018
The Office of Cancer Clinical Proteomics Research of the National Cancer Institute (NCI), part of the National Institutes of Health, announces the release of a video titled, “International Cancer Proteogenome Consortium (ICPC)”. Launched during the 2018 Human Proteome Organization World Congress, the...
September 24, 2018
The National Cancer Institute in partnership with the Food and Drug Administration is pleased to announce the launch of the precisionFDA NCI-CPTAC Multi-Omics Challenge. The aim of this crowd-...
September 7, 2018
Multidimensional multi-omics datasets from The Cancer Genome Atlas (TCGA), the Clinical Proteomic Tumor Analysis Consortium (CPTAC), and similar initiatives are becoming a powerful approach to...
August 23, 2018
Next-generation mass spectrometry (NGMS) has become a powerful tool for protein identification and quantification from prospectively collected fresh frozen or optimal cutting temperature embedded specimens. However, limitations due to supply, accessibility, and delay of clinical information and...
August 8, 2018
In biomedical research, sample mislabeling or incorrect annotation has been a long-standing problem that contributes to irreproducible results and invalid conclusions. These problems are particularly prevalent in large scale multi-omics studies where human errors could arise during sample...
July 19, 2018
In recent years, proteomic technologies have emerged as invaluable tools in cancer research. Next-generation mass spectrometry (NGMS) is being used to study cancer biology, while providing the cancer research community with a growing body of biological knowledge that may lead to more effective drug...
July 9, 2018
Acute myeloid leukemia (AML) is a heterogenous malignancy that stems from the production of abnormal white blood cells, platelets, or red blood cells in the bone marrow. It is estimated that 19,520 new...
June 25, 2018
In an effort to improve rigor and reproducibility, the National Cancer Institute (NCI) Antibody Characterization Program requests cancer-related protein targets for monoclonal antibody production and...
May 9, 2018
Eleven experts were interviewed in a series of videos titled Perspectives in Proteomics at the Human Proteome Organization World Congress (HUPO 2017) in Dublin, Ireland this past fall.
May 7, 2018
The National Cancer Institute’s (NCI) Office of Cancer Clinical Proteomics Research, part of the National Institutes of Health, along with the Indian Institute of Technology Bombay (IITB) and Tata Memorial Centre (TMC) have signed...
May 1, 2018
In an effort to provide well-characterized monoclonal antibodies to the scientific community, the National Cancer Institute (NCI) Antibody Characterization Program requests cancer-related protein...
April 23, 2018
An estimated 252,710 new cases of female breast cancer, accounting for 15% of all new cancer cases, occurred in 2017. To better understand proteogenomic abnormalities in breast cancer, the National Cancer Institute (NCI) Clinical...
April 19, 2018
Precision medicine is an approach that allows doctors to understand how a patient's genetic profile may cause cancer to grow and spread, leading to a...